Simplex Trading’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Simplex Trading’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$383K	Sell	78,904 -19,650	-20%	-$78.4K	﹤0.01%	3947
2026 Q1	$231K	Buy	+98,554	New	+$255K	﹤0.01%	4135
2025 Q3	–	Sell	-9,699	Closed	-$14.5K	–	10251
2025 Q2	$11K	Buy	9,699 +8,154	+528%	+$10.8K	﹤0.01%	7278
2025 Q1	$2K	Buy	+1,545	New	+$3.33K	﹤0.01%	8108
2024 Q4	–	Sell	-267	Closed	-$875	–	9805
2024 Q3	$0	Sell	267 -300	-53%	-$1.09K	﹤0.01%	9754
2024 Q2	$2K	Buy	+567	New	+$6.33K	﹤0.01%	8371
2024 Q1	–	Sell	-31,078	Closed	-$427K	–	10089
2023 Q4	$470K	Buy	31,078 +28,865	+1,304%	+$421K	﹤0.01%	3768
2023 Q3	$44K	Buy	+2,213	New	+$56.2K	﹤0.01%	5933

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Simplex Trading's ZNTL Position: Q2 2026 in Review

Simplex Trading reduced its Zentalis Pharmaceuticals (ZNTL) stake by 20% in Q2 2026, selling an estimated $78.4K and leaving 78,904 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

Simplex Trading first reported a position in ZNTL in Q3 2023 and has held it in 8 quarters since. The position peaked at $470K in Q4 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Simplex Trading held 78,904 shares of Zentalis Pharmaceuticals worth $383K as of Q2 2026.
Simplex Trading sold 19,650 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $78.4K.
Zentalis Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3947 holding.
Simplex Trading first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Simplex Trading's Zentalis Pharmaceuticals position peaked at $470K in Q4 2023.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.